ArticleVaccine2022
Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project.
Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review.Advances in therapy · 2023Pooled it
- Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.Nature communications · 2025Trial
- Influenza vaccine awareness and uptake patterns among women of reproductive age in Pudong New Area: A community-based cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Continuity of Vaccination Across the Life Course: Poland in Comparison with Selected EU/EEA Countries and the United Kingdom.Vaccines · 2026Review
- Article
- Strain Agnostic Influenza Virus Propagation in a Serum-Free, Suspension-Adapted MDCK Cell Line.Influenza and other respiratory viruses · 2026Article
- Article
- Procalcitonin-guided antibiotic prescription in patients with respiratory syncytial virus and influenza virus.BMJ open respiratory research · 2025Article
- Safety monitoring of GSK's quadrivalent seasonal influenza vaccine in European countries during the 2023/24 flu season: A multicenter, non-interventional study.Human vaccines & immunotherapeutics · 2025Observational
- Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020.Open forum infectious diseases · 2025Article
- Disease burden of influenza in Spain: A five-season study (2015-2020).Human vaccines & immunotherapeutics · 2025Article
- Review
- Influenza Vaccine Effectiveness During the 2023/2024 Season: A Test-Negative Case-Control Study Among Emergency Hospital Admissions With Respiratory Conditions in Northern Ireland.Influenza and other respiratory viruses · 2025Article
- Influenza A vs. COVID-19: A Retrospective Comparison of Hospitalized Patients in a Post-Pandemic Setting.Microorganisms · 2025Article
- Influenza vaccination in older people: a geriatrician's perspective.Aging clinical and experimental research · 2025Review
- Molecular biophysics and inhibition mechanism of influenza virus A M2 viroporin by adamantane-based drugs - Challenges in designing antiviral agents.Journal of structural biology: X · 2025Article
- Disease Burden of RSV Infection in Adult Patients in Comparison to Influenza Virus Infection.Journal of medical virology · 2025Article
- Influenza-Related Deaths in the Czech Republic Over 21 Seasons.Influenza and other respiratory viruses · 2025Article
- Individual associations of self-reported sleep duration, sleep quality, chronotype and social jet lag with infectious disease risk.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe European Centres for Disease Prevention and Control (ECDC) estimates that seasonal influenzacauses 4-50 million symptomatic infections in the EU/EEA each year and 15,000-70,000 European citizens die of causes associated with influenza. We used modelling methods to estimate influenza-associated mortality for the European Union by age group and country.
methodsWe compiled influenza-associated respiratory mortality estimates for 31 countries around the world (11 countries in the EU) during 2002-2011 (excluding the 2009 pandemic). From these we extrapolated the influenza mortality burden for all 193 countries of the world, including the 28 countries of the EU, using a multiple imputation approach. To study the effect of vaccination programs, we obtained data from the EU-funded VENICE project regarding the percentage of persons over 65 who were vaccinated in each country; the data ranged from 2% to 82% between the 21 countries which provided estimates for the 2006/07 reference season.
resultsWe estimated that an average of 27,600 (range 16,200-39,000) respiratory deaths were associated with seasonal influenza in the 28 EU countries per winter; 88% were among people 65 years and older, and the rates of mortality in this age group were roughly 35 times higher compared with those < 65 years. Estimates varied considerably across the EU; for example, rates in the elderly ranged from 21.6 (12.5-35.1) per 100,000 in Portugal to 36.5 (16.4-62.5) in Luxembourg, a difference of nearly 70%. We were unable to find a negative correlation between vaccination coverage rates and influenza-associated mortality estimates in the elderly.
conclusionOur EU estimate of influenza-associated respiratory mortality is broadly consistent with the ECDC estimate. More research is needed to explain the observed variation in mortality across the EU, and on possible bias that could explain the unexpected lack of mortality benefits associated with European elderly influenza vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.